<p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）在周一发布的一份报告中，Leerink Partners 的股票研究人员将其目标价格从 456.00 美元上调至 525.00 美元，Benzinga 报道。该公司目前对这家制药公司的股票给予 “跑赢大盘” 的评级。Leerink Partners 的目标价格表明，相较于股票当前价格，存在 13.42% 的潜在上涨空间。</p>
<ul>
<li>Royalty Pharma 如何在不承担生物技术最大风险的情况下盈利</li>
</ul>
<p>其他一些股票研究分析师也最近对该股票发表了评论。Weiss Ratings 在 10 月 8 日的报告中重申了对 Vertex Pharmaceuticals 股票的 “持有（c+）” 评级。Leerink Partners 在 9 月 25 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “持有” 上调至 “强力买入”。富国银行在 12 月 10 日的研究报告中将 Vertex Pharmaceuticals 的目标价格从 460.00 美元上调至 515.00 美元，并给予该公司 “超配” 的评级。摩根大通在 10 月 8 日的研究报告中将 Vertex Pharmaceuticals 的目标价格从 517.00 美元上调至 530.00 美元，并给予该股票 “超配” 的评级。最后，Evercore ISI 在 9 月 11 日的报告中将 Vertex Pharmaceuticals 的目标价格从 510.00 美元下调至 475.00 美元，并对该股票设定了 “跑赢大盘” 的评级。三位研究分析师对该股票给予了强力买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 502.05 美元。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<p><strong>阅读我们关于 VRTX 的最新报告</strong></p>
<h2>Vertex Pharmaceuticals 股票下跌 0.0%</h2>
<ul>
<li>2025 年最佳生物技术股票</li>
</ul>
<p>纳斯达克：VRTX 周一开盘价为 462.90 美元。Vertex Pharmaceuticals 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。该股票的 50 日简单移动平均线为 435.77 美元，200 日简单移动平均线为 426.18 美元。该公司的市值为 1174.5 亿美元，市盈率为 32.64，贝塔值为 0.32。</p>
<p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近在 11 月 3 日发布了季度财报。该制药公司报告本季度每股收益为 4.80 美元，超出市场共识预期的 4.58 美元，超出幅度为 0.22 美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。该公司本季度的收入为 30.8 亿美元，而市场共识预期为 30.5 亿美元。在去年同期，该公司每股收益为 4.38 美元。与去年同期相比，该公司的收入增长了 11.0%。分析师预计，Vertex Pharmaceuticals 在当前财年将发布 15.63 美元的每股收益。</p>
<h2>内部活动</h2>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>在其他新闻中，执行副总裁 Charles F. Wagner, Jr.在 12 月 3 日的交易中出售了 14,000 股 Vertex Pharmaceuticals 的股票。该股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。出售后，该执行副总裁直接持有该公司 37,725 股，价值 17,202,600 美元。此次交易使其持股减少了 27.07%。该交易在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，董事长 Jeffrey M. Leiden 在 12 月 3 日的交易中出售了 63,781 股公司的股票。该股票以平均价格 449.20 美元出售，总交易额为 28,650,425.20 美元。交易完成后，董事长直接持有该公司 24,026 股，价值 10,792,479.20 美元。此次交易使其持股减少了 72.64%。SEC 对该销售的文件提供了更多信息。在过去 90 天内，内部人士已出售 151,073 股公司股票，价值 67,326,816 美元。公司内部人士持有 0.20% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。挪威银行在第二季度购买了 Vertex Pharmaceuticals 的新股份，价值约为 15.93974 亿美元。资本国际投资者在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 77.9%。资本国际投资者目前持有 4,689,059 股该制药公司的股票，价值 18.3655 亿美元，此前在该期间内又购买了 2,053,156 股。Jennison Associates LLC 在第二季度将其在 Vertex Pharmaceuticals 的持仓提高了 21.5%。Jennison Associates LLC 目前持有 6,151,505 股该制药公司的股票，价值 27.3865 亿美元，此前在上个季度又购买了 1,089,063 股。Assenagon 资产管理公司在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 214.6%。Assenagon 资产管理公司目前持有 763,703 股该制药公司的股票，价值 2.99097 亿美元，此前在该期间内又购买了 520,949 股。最后，先锋集团在第二季度将其在 Vertex Pharmaceuticals 的持仓增加了 2.1%。先锋集团目前持有 23,973,777 股该制药公司的股票，价值 106.73126 亿美元，此前在上个季度又购买了 482,616 股。机构投资者持有该公司 90.96% 的股票。</p>
<h2>Vertex Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病的治疗方法的发现、开发和商业化。成立于 1989 年，Vertex 凭借以研究为驱动的药物开发建立了声誉，最为人知的是其在囊性纤维化（CF）方面的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
<p>Vertex 的上市产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Vertex Pharmaceuticals 更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>100 万美元在退休后能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>Leerink Partners 已将 Vertex Pharmaceuticals（纳斯达克代码：VRTX）的目标股价从 456.00 美元上调至 525.00 美元，维持 “跑赢大盘” 的评级。这个新目标暗示从当前股价来看有 13.42% 的潜在上涨空间。其他分析师也给出了不同的评级，普遍评级为 “适度买入”，目标股价为 502.05 美元。Vertex 最近的季度财报显示每股收益为 4.80 美元，超出预期，营收同比增长 11%。内部交易活动中，高管们进行了大量股票出售</p>

<p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price target raised by equities researchers at Leerink Partners from $456.00 to $525.00 in a report issued on Monday,Benzinga reports. The firm currently has an &#34;outperform&#34; rating on the pharmaceutical company's stock. Leerink Partners' target price indicates a potential upside of 13.42% from the stock's current price.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）在周一发布的一份报告中，Leerink Partners 的股票研究人员将其目标价格从 456.00 美元上调至 525.00 美元，Benzinga 报道。该公司目前对这家制药公司的股票给予 “跑赢大盘” 的评级。Leerink Partners 的目标价格表明，相较于股票当前价格，存在 13.42% 的潜在上涨空间。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在不承担生物技术最大风险的情况下盈利</li>
</ul>
</div><p>A number of other equities research analysts have also recently commented on the stock. Weiss Ratings restated a &#34;hold (c+)&#34; rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. Leerink Partnrs raised shares of Vertex Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, September 25th. Wells Fargo &amp; Company raised their target price on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. JPMorgan Chase &amp; Co. upped their price target on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, October 8th. Finally, Evercore ISI cut their price target on Vertex Pharmaceuticals from $510.00 to $475.00 and set an &#34;outperform&#34; rating on the stock in a report on Thursday, September 11th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $502.05.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也最近对该股票发表了评论。Weiss Ratings 在 10 月 8 日的报告中重申了对 Vertex Pharmaceuticals 股票的 “持有（c+）” 评级。Leerink Partners 在 9 月 25 日的研究报告中将 Vertex Pharmaceuticals 的评级从 “持有” 上调至 “强力买入”。富国银行在 12 月 10 日的研究报告中将 Vertex Pharmaceuticals 的目标价格从 460.00 美元上调至 515.00 美元，并给予该公司 “超配” 的评级。摩根大通在 10 月 8 日的研究报告中将 Vertex Pharmaceuticals 的目标价格从 517.00 美元上调至 530.00 美元，并给予该股票 “超配” 的评级。最后，Evercore ISI 在 9 月 11 日的报告中将 Vertex Pharmaceuticals 的目标价格从 510.00 美元下调至 475.00 美元，并对该股票设定了 “跑赢大盘” 的评级。三位研究分析师对该股票给予了强力买入评级，十五位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 502.05 美元。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 VRTX 的最新报告</strong></p>
</div><h2>Vertex Pharmaceuticals Stock Down 0.0%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票下跌 0.0%</h2>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票</li>
</ul>
</div><p>NASDAQ:VRTX opened at $462.90 on Monday. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $519.68. The stock's 50-day simple moving average is $435.77 and its 200 day simple moving average is $426.18. The firm has a market capitalization of $117.45 billion, a PE ratio of 32.64 and a beta of 0.32.</p>
<div class="lb-trans"><p>纳斯达克：VRTX 周一开盘价为 462.90 美元。Vertex Pharmaceuticals 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。该股票的 50 日简单移动平均线为 435.77 美元，200 日简单移动平均线为 426.18 美元。该公司的市值为 1174.5 亿美元，市盈率为 32.64，贝塔值为 0.32。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the prior year, the firm earned $4.38 EPS. The firm's revenue was up 11.0% compared to the same quarter last year. On average, analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克代码：VRTX - 获取免费报告）最近在 11 月 3 日发布了季度财报。该制药公司报告本季度每股收益为 4.80 美元，超出市场共识预期的 4.58 美元，超出幅度为 0.22 美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。该公司本季度的收入为 30.8 亿美元，而市场共识预期为 30.5 亿美元。在去年同期，该公司每股收益为 4.38 美元。与去年同期相比，该公司的收入增长了 11.0%。分析师预计，Vertex Pharmaceuticals 在当前财年将发布 15.63 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>In other news, EVP Charles F. Wagner, Jr. sold 14,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the sale, the executive vice president directly owned 37,725 shares in the company, valued at $17,202,600. The trade was a 27.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the business's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the completion of the transaction, the chairman directly owned 24,026 shares in the company, valued at $10,792,479.20. This trade represents a 72.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 151,073 shares of company stock worth $67,326,816. 0.20% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Charles F. Wagner, Jr.在 12 月 3 日的交易中出售了 14,000 股 Vertex Pharmaceuticals 的股票。该股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。出售后，该执行副总裁直接持有该公司 37,725 股，价值 17,202,600 美元。此次交易使其持股减少了 27.07%。该交易在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，董事长 Jeffrey M. Leiden 在 12 月 3 日的交易中出售了 63,781 股公司的股票。该股票以平均价格 449.20 美元出售，总交易额为 28,650,425.20 美元。交易完成后，董事长直接持有该公司 24,026 股，价值 10,792,479.20 美元。此次交易使其持股减少了 72.64%。SEC 对该销售的文件提供了更多信息。在过去 90 天内，内部人士已出售 151,073 股公司股票，价值 67,326,816 美元。公司内部人士持有 0.20% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter worth approximately $1,593,974,000. Capital International Investors increased its holdings in shares of Vertex Pharmaceuticals by 77.9% in the third quarter. Capital International Investors now owns 4,689,059 shares of the pharmaceutical company's stock worth $1,836,550,000 after purchasing an additional 2,053,156 shares during the period. Jennison Associates LLC raised its position in shares of Vertex Pharmaceuticals by 21.5% in the second quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company's stock worth $2,738,650,000 after buying an additional 1,089,063 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Vertex Pharmaceuticals by 214.6% during the third quarter. Assenagon Asset Management S.A. now owns 763,703 shares of the pharmaceutical company's stock valued at $299,097,000 after buying an additional 520,949 shares during the period. Finally, Vanguard Group Inc. grew its position in Vertex Pharmaceuticals by 2.1% during the second quarter. Vanguard Group Inc. now owns 23,973,777 shares of the pharmaceutical company's stock worth $10,673,126,000 after buying an additional 482,616 shares in the last quarter. Institutional investors own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。挪威银行在第二季度购买了 Vertex Pharmaceuticals 的新股份，价值约为 15.93974 亿美元。资本国际投资者在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 77.9%。资本国际投资者目前持有 4,689,059 股该制药公司的股票，价值 18.3655 亿美元，此前在该期间内又购买了 2,053,156 股。Jennison Associates LLC 在第二季度将其在 Vertex Pharmaceuticals 的持仓提高了 21.5%。Jennison Associates LLC 目前持有 6,151,505 股该制药公司的股票，价值 27.3865 亿美元，此前在上个季度又购买了 1,089,063 股。Assenagon 资产管理公司在第三季度将其在 Vertex Pharmaceuticals 的持股增加了 214.6%。Assenagon 资产管理公司目前持有 763,703 股该制药公司的股票，价值 2.99097 亿美元，此前在该期间内又购买了 520,949 股。最后，先锋集团在第二季度将其在 Vertex Pharmaceuticals 的持仓增加了 2.1%。先锋集团目前持有 23,973,777 股该制药公司的股票，价值 106.73126 亿美元，此前在上个季度又购买了 482,616 股。机构投资者持有该公司 90.96% 的股票。</p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Inc 是一家总部位于波士顿的生物技术公司，专注于严重疾病的治疗方法的发现、开发和商业化。成立于 1989 年，Vertex 凭借以研究为驱动的药物开发建立了声誉，最为人知的是其在囊性纤维化（CF）方面的工作，其小分子 CFTR 调节剂的产品组合改变了许多患者的治疗标准。该公司在多个国际市场运营研究与开发、制造和商业组织，为患者和医疗系统提供服务。</p>
</div><p>Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.</p>
<div class="lb-trans"><p>Vertex 的上市产品集中在 CFTR 调节剂上，这些药物针对囊性纤维化的根本原因，而不仅仅是治疗症状。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Vertex Pharmaceuticals 更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>100 万美元在退休后能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Leerink Partners 将福泰制药（NASDAQ:VRTX）的目标价上调至 525.00 美元